The present invention relates to a composition comprising an antibacterial agent in an amount insufficient to provide antibacterial effect, a physiologically acceptable divalent metal ion in a very low concentration and a physiologically acceptable polymer for preventing and/or treating halitosis, bad breath, dry mouth or sore throat.

The present invention relates to a composition comprising an antibacterial agent in an amount insufficient to provide antibacterial effect, a physiologically acceptable divalent metal ion in a very low concentration and a physiologically acceptable polymer for preventing and/or treating halitosis, bad breath, dry mouth or sore throat.

The present disclosure encompasses combinations of ralinepag with a cGMP-elevating agent or prostanoid such as riociguat, treprostinil, or iloprost for treating PAH. The disclosed combination therapy provides for advantages such as improved efficacy, improved safety, reduced doses and/or frequency of ralinepag and/or riociguat, reduced doses and/or frequency of ralinepag and/or treprostinil, and reduced doses and/or frequency of ralinepag and/or iloprost. In some embodiments, the clinical effectiveness of a reduced dose combination is additive or synergistic compared to that provided by the corresponding ralinepag, riociguat, treprostinil, and/or iloprost monotherapies.